AstraZeneca pays $5.5 million to resolve China, Russia FCPA offenses
The Securities and Exchange Commission Tuesday charged U.K.-based pharma AstraZeneca PLC with violating the books and records and internal controls provisions of the Foreign Corrupt Practices Act when wholly-owned subsidiaries in China and Russia made illegal payments to boost drug sales.… Continue Reading